Streetbeat News

Regulatory

HSDT

Helius Medical Technologies announced that the Centers for Medicare & Medicaid Services (CMS) has released its preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece, indicating a positive step towards reimbursement for these devices.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 1:02 pm

BYDDF

F

GM

TSLA

Chinese EVs face a significant barrier entering the U.S. market due to a 27.5% import tariff, impacting their competitiveness against U.S. automakers like Ford, General Motors, and Tesla. Despite their popularity globally, these tariffs, alongside concerns over national security and environmental advocacy, limit their market penetration in the U.S. Meanwhile, U.S. companies are developing more affordable EV models, with Tesla planning a lower-priced EV launch next year. The Biden administration is balancing affordable EV promotion with American job protection, maintaining or potentially increasing tariffs.

Portfolio Pulse from Benzinga Neuro

May 06, 2024 | 12:58 pm

FXI

China's President Xi Jinping has refuted claims that China is facing an overcapacity issue, according to a report by Xinhua. This statement comes amid ongoing discussions about the state of China's economy and its impact on global markets.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:51 pm

ALLR

Allarity Therapeutics' shares surged following the announcement that its stockholders' equity exceeds the $2.5 million Nasdaq minimum requirement. The company plans to request the SEC to withdraw Form S-1.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:50 pm

HOOD

Robinhood expressed disappointment after the SEC issued a 'Wells Notice', indicating potential regulatory action. The company firmly believes that the assets listed on its platform are not securities, suggesting a disagreement with the SEC's stance.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:46 pm

CYBN

Cybin Inc. (CYBN) announced updates on its clinical programs, including the expected initiation of a Phase 3 study for CYB003 in MDD by mid-2024 and Phase 2 results for CYB004 in GAD by Q4 2024. The company secured a $150 million funding round and received FDA Breakthrough Therapy Designation for CYB003. CYB003 showed promising Phase 2 results in MDD treatment, and CYB004 is in development for GAD, with a Phase 2 study underway. Cybin's intellectual property portfolio includes over 50 granted patents and 170 pending applications related to psychedelic-based treatments.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:42 pm

KULR

KULR Technology Group, Inc. (NYSE:KULR) has regained compliance with NYSE American's continued listing standards, resolving a deficiency related to the low selling price of its common stock. The company achieved sustained price improvement, reflecting its commitment to enhancing stockholder value and optimizing long-term public valuation.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:40 pm

RDFN

Redfin has agreed to a proposed settlement of $9.25 million to resolve the nationwide class action litigation, Gibson v. NAR, No. 4:23-cv-00788. The settlement requires Redfin to pay into a Qualified Settlement Fund within 30 days following the court's preliminary approval of the settlement agreement, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:38 pm

JAGX

The FDA has conditionally approved Jaguar Health's prescription drug Crofelemer for treating chemotherapy-induced diarrhea in dogs. Diarrhea is a leading cause for veterinary visits, with no FDA-approved anti-secretory agents available for treatment until now.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:35 pm

NRXP

NRx Pharmaceuticals announced the final results of its clinical trial, indicating that its drug NRX-101 has shown to reduce akathisia while maintaining comparable antidepressant efficacy. The company believes these results may constitute a basis for seeking accelerated FDA approval for NRX-101.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:34 pm